Observational multicentric national longitudinal study evaluating Ibrance (palbociclib) in a real life setting conditions in patients 70 years old and older presenting a locally advanced or metastatic HR+/HER2- breast cancer
Latest Information Update: 29 Jun 2023
At a glance
- Drugs Palbociclib (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms PALOMAGE
- 06 Jun 2023 Results of cohort A (n=362; from 130 sites) based on the rate of PAL discontinuation at 18 months for any reason as the primary endpoint, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 22 Jul 2021 New trial record
- 08 Jun 2021 Results (10/2018 to 10/2020, n=807) presented at the 57th Annual Meeting of the American Society of Clinical Oncology.